Glaxosmithkline Pharmaceuticals Ltd Share Price (GLAXO)

GlaxoSmithKline Pharmaceuticals Limited is one of the leading pharmaceutical companies in India, with its subsidiary GlaxoSmithKline plc UK being one of the largest global research-based pharmaceutical and healthcare companies. The Company deals with manufacturing, distributing, and trading in pharmaceuticals and offers an extensive range of prescription medicines and vaccines across therapeutic areas like Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease, and Respiratory Diseases. Two manufacturing units in India are located at Nashik and Thane and a clinical development centre in Bangalore. Birth of this pharmaceutical company was marked in 1924 and since then there have been numerous achievements in terms of sales, market reputation, and product launches. During 1991, the Company entered into an agreement with CSIR and in the same year SmithKline Beecham became Eskayef Limited. In the year 1994, Family Products Division was sold to H J Heinz followed by a joint venture project with Eisai Pharmaceuticals in 1998 and Novartis Healthcare Pvt. Ltd. in 2015. GlaxoSmithKline Pharma has launched various products and brands like Cetzine, Seretide, Windia, Windamet, Boostrix, Infanrix, Parit, Carryec, Zimig, Carzec, Zemetril, Benitec, Zobactin, Olmesatan, Cobadex CZS, Mycamine, Prioix , Parit D, Esbanen, and Metered Dose Inhaler with Dose Counter. The Company has allotted 84,70,3017 Bonus Shares in Sep 2018 and recently invested Rs 1000 crore in the new manufacturing facility at Vemgal, Karnataka. Additionally, products like Menveo, EnteroPlus, Neosporin, Votrient, Revolade, Biopatch, Fluarix Tetra, Nucala, and Trevely Ellipta have been launched within the past 3 years with considerable success in the market. The Company is constantly making significant progress with immense success in terms of sales, reputation, and product launches.

Share Price: ₹1871.20 per share as on 19 Apr, 2024 04:01 PM
Market Capitalisation: ₹31,986.40Cr as of today
Revenue: ₹805.26Cr as on December 2023 (Q4 23)
Net Profit: ₹45.72Cr as on December 2023 (Q4 23)
Listing date: 03 Nov, 1994
Chairperson Name: Renu S Karnad